Compare Teucrium Soybean Fund (SOYB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs Spyre Therapeutics Inc. Common Stock — how do they compare? Teucrium Soybean Fund trades at $27.2 (market cap $43.28M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 173.8× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Soybean Fund for 25 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SOYB | SYRE | |
|---|---|---|
Market Cap | $43.28M | $7.52B |
Volume | 28,719 | 1,441,031 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $28.14 | $108.92 |
52-Week Low | $21.59 | $22.18 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $27.33, down 0.51% today, with a bullish technical signal driven by moving averages. The stock is consolidating near key support at $27, with neutral oscillators indicating limited momentum. Recent news highlights potential catalysts from U.S.-China trade talks, which could boost soybean demand.
The outlook hinges on trade developments and commodity price trends, offering upside if diplomatic progress materializes. Risks include geopolitical tensions and commodity market volatility. Analyst sentiment appears cautiously optimistic, but fundamental data remains sparse for detailed assessment.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
